data posit three shot
immunogen serotyp safeti in-line
announc preliminari result phase infant studi
pneumococc vaccin follow-on prevnar first three dose induc
immun respons serotyp demonstr safeti profil similar
pr mention whether show statist
non-inferior overlap serotyp compani believ
hit proof-of-concept mileston howev plan wait data
fourth dose formal strategi conjunct regul
expect initi infant studi set behind
meanwhil adult indic complet enrol three on-going
studi continu target bla submiss recal pfe
seven addit serotyp vs pfe market-lead
merck two addit serotyp mrk alreadi
trial adult infant popul believ preliminari result
encourag given readout overhang detail data still need
assess posit vs mrk next-gen pneumococc vaccin
space reiter po skeptic share command
pe despit remainco ex-upjohn offer attract growth profil
also report complet enrol three studi adult
popul yr primari complet dec pfe continu
target bla file adult indic believ posit
achiev similar timelin base on-going studi recal june cdc center
diseas control advisori committe immun practic acip downgrad
recommend pfe use adult age physician discret
routin
competit behind infant pcv
previous outlin link increment advanc repres next-gen
vaccin base serotyp coverag estim reduct ipd event rate
dramat rel exist option else-equ physician would prefer
vaccin give broadest coverag although detail data
need determin extent new vaccin trade-off efficaci serotyp
alreadi cover given rel scope ad coverag next-
gen expect acip issu definit recommend prevnar
thu would expect high degre market disrupt
year market ahead
net dbt
cdc center diseas control
acip advisori committe
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
price object po base part sotp analysi includ
remainco stake upjohn-myl
remainco assum compani trade multipl ep
remainco vs current averag us/eu pharma group
risk sale downsid us sale continu declin and/or competit
take meaning market share ibranc could lead downsid estim
po inabl grow busi line forecast hold opex
spend flat level throughout forecast period transact
perceiv valu destruct
jason gerberri herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
invest opinion system contain end report head fundament equiti opinion dark grey shade indic secur restrict opinion suspend medium grey
shade indic secur review opinion withdrawn grey shade indic secur cover chart current august later date indic
equiti invest rate distribut health group jun
equiti invest rate distribut global group jun
issuer invest bank client bofa merril lynch one affili within past month purpos invest rate distribut coverag univers includ stock
stock rate neutral includ hold stock rate under-perform includ sell
fundament equiti opinion opinion includ volatil risk rate invest rate incom rate volatil risk rate indic potenti
price fluctuat medium high invest rate reflect analyst assess stock absolut total return potenti ii
attract invest rel stock within coverag cluster defin three invest rate buy stock expect total
return least attract stock coverag cluster neutral stock expect remain flat increas valu less attract
buy rate stock under-perform stock least attract stock coverag cluster analyst assign invest rate consid among thing
month total return expect stock firm guidelin rate dispers shown tabl current price object stock
referenc better understand total return expect given time price object reflect analyst view potenti price appreci depreci
total return expect within period date initi rate
rate dispers guidelin coverag cluster
rate dispers may vari time time bofa merril lynch research believ better reflect invest prospect stock coverag cluster
incom rate indic potenti cash dividend same/high dividend consid secur same/low dividend consid secur pay
cash dividend coverag cluster compris stock cover singl analyst two analyst share common industri sector region classif stock
coverag cluster includ recent bofa merril lynch report referenc stock
price chart secur referenc research report avail http //pricechart baml com call mail
bofa one affili act market maker equiti secur recommend report
bofa affili manag public offer secur issuer within last month
issuer within last month invest bank client bofa and/or one affili
bofa affili receiv compens issuer non-invest bank servic product within past month
issuer within last month non-secur busi client bofa and/or one affili
bofa affili receiv compens invest bank servic issuer within past month
bofa affili expect receiv intend seek compens invest bank servic issuer affili issuer within next three month
bofa togeth affili benefici own one percent common stock issuer report issu day month reflect
ownership posit last day previou month report issu day month reflect ownership posit end second month preced date
report
bofa one affili will sell buy client common equiti issuer princip basi
issuer within last month secur busi client non-invest bank bofa and/or one affili
bofa merril lynch research personnel includ analyst respons report receiv compens base upon among factor overal profit america
corpor includ profit deriv invest bank analyst respons report may also receiv compens base upon among factor overal
profit bank sale trade busi relat class secur financi instrument analyst respons
